Approved drugs offer the potential to generate significant value in new therapeutic uses. Proven safety reduces development risk/cost and increases speed to clinic/market versus traditional biotech models. Our approach harnesses these strategic advantages:

  • Identify known drug molecules with the potential to function as innovative therapies for unmet medical needs.
  • Use cocrystal technology to protect and enable new commercially attractive product opportunities.
  • Lower-risk human studies will provide validation to support out-licensing and further development by partners.
  • Balanced pipeline combines assets for early out-licensing with those offering significant mid-term partnering potential.
  • Early revenues allow self-funding of future discovery and development to build greater value into our pipeline.